Falcon Point Capital’s AMAG Pharmaceuticals AMAG Stock Holding History

Falcon Point Capital’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-330,819	Closed	-$6.62M	–	115
2018 Q3	$6.62M	Sell	330,819 -455,977	-58%	-$10.4M	1.42%	33
2018 Q2	$15.3M	Buy	786,796 +67,721	+9%	+$1.5M	3.01%	2
2018 Q1	$14.5M	Buy	719,075 +33,838	+5%	+$572K	2.9%	2
2017 Q4	$9.08M	Sell	685,237 -154,240	-18%	-$2.33M	1.53%	33
2017 Q3	$13.2M	Buy	839,477 +167,175	+25%	+$3.12M	1.91%	21
2017 Q2	$12.4M	Sell	672,302 -20,698	-3%	-$410K	1.67%	30
2017 Q1	$15.6M	Sell	693,000 -108,944	-14%	-$2.61M	2.08%	17
2016 Q4	$27.9M	Sell	801,944 -79,082	-9%	-$2.36M	3.74%	1
2016 Q3	$22.6M	Buy	881,026 +169,254	+24%	+$4.23M	3.46%	2
2016 Q2	$17M	Buy	711,772 +330,691	+87%	+$7.58M	2.94%	3
2016 Q1	$8.92M	Buy	+381,081	New	+$9.04M	1.54%	33

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Falcon Point Capital's AMAG Position: Q4 2018 in Review

Falcon Point Capital sold out of AMAG Pharmaceuticals (AMAG) in Q4 2018, closing a stake of 330,819 shares — an estimated $6.62M sold.

Falcon Point Capital first reported a position in AMAG in Q1 2016 and held it in 11 quarters. The position peaked at $27.9M in Q4 2016. 190 funds tracked by Wall St. Rank hold AMAG as of Q4 2018.

Falcon Point Capital reported no remaining AMAG Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Falcon Point Capital sold 330,819 AMAG Pharmaceuticals shares in Q4 2018, an estimated $6.62M.
Falcon Point Capital first reported a position in AMAG Pharmaceuticals in Q1 2016 and held it in 11 quarters.
Falcon Point Capital's AMAG Pharmaceuticals position peaked at $27.9M in Q4 2016.
190 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2018.

Based on Falcon Point Capital's 13F filing for Q4 2018, filed 31 Jan 2019.